184 related articles for article (PubMed ID: 32236406)
21. Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance.
Ellsworth M; Ostrosky-Zeichner L
J Fungi (Basel); 2020 Nov; 6(4):. PubMed ID: 33260353
[TBL] [Abstract][Full Text] [Related]
22. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
Rausch CR; DiNardo CD; Maiti A; Jammal NJ; Kadia TM; Marx KR; Borthakur G; Savoy JM; Pemmaraju N; DiPippo AJ; Daver NG; Chew SM; Sasaki K; Issa GC; Short NJ; Takahashi K; Ohanian MN; Ning J; Xiao L; Alvarado Y; Kontoyiannis DP; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Jul; 127(14):2489-2499. PubMed ID: 33793970
[TBL] [Abstract][Full Text] [Related]
23. Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients.
Klatt ME; Eschenauer GA
J Fungi (Basel); 2021 Jan; 7(2):. PubMed ID: 33499209
[TBL] [Abstract][Full Text] [Related]
24. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
25. A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of
Blomquist KC; Nix DE
Ann Pharmacother; 2021 Aug; 55(8):1010-1024. PubMed ID: 33228374
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Nolan PJ; Jain R; Cohen L; Finklea JD; Smith TT
Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115204. PubMed ID: 33152675
[TBL] [Abstract][Full Text] [Related]
27. Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.
McCreary EK; Nguyen MH; Davis MR; Borlagdan J; Shields RK; Anderson AD; Rivosecchi RM; Marini RV; Sacha LM; Silveira FP; Andes DR; Lepak AJ
J Antimicrob Chemother; 2020 Oct; 75(10):3023-3028. PubMed ID: 32710097
[TBL] [Abstract][Full Text] [Related]
28. Isavuconazole for invasive fungal infections.
Aust Prescr; 2020 Jun; 43(3):100-101. PubMed ID: 32675914
[No Abstract] [Full Text] [Related]
29. Isavuconazole Therapy of Disseminated and Encephalic
Perrone S; Lisi C; La Barbera EO; Luise C; Lichtner M; Girmenia C; Cimino G
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020026. PubMed ID: 32395215
[TBL] [Abstract][Full Text] [Related]
30. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
Koehler P; Bassetti M; Chakrabarti A; Chen SCA; Colombo AL; Hoenigl M; Klimko N; Lass-Flörl C; Oladele RO; Vinh DC; Zhu LP; Böll B; Brüggemann R; Gangneux JP; Perfect JR; Patterson TF; Persigehl T; Meis JF; Ostrosky-Zeichner L; White PL; Verweij PE; Cornely OA; ; ; ; ; ; ; ; ; ; ; ; ; ;
Lancet Infect Dis; 2021 Jun; 21(6):e149-e162. PubMed ID: 33333012
[TBL] [Abstract][Full Text] [Related]
31. Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center.
Borman AM; Hughes JM; Oliver D; Fraser M; Sunderland J; Noel AR; Johnson EM
Med Mycol; 2020 Oct; 58(7):996-999. PubMed ID: 32396168
[TBL] [Abstract][Full Text] [Related]
32. Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents.
Miller MA; Molina KC; Gutman JA; Scherger S; Lum JM; Mossad SB; Burgess M; Cheng MP; Chuang ST; Jacobs SE; Melendez DP; Shah DP; Zimmer A; Sohail MR; Syed S; Walker RC; Poeschla EM; Abidi MZ
Open Forum Infect Dis; 2021 Feb; 8(2):ofaa646. PubMed ID: 33575424
[TBL] [Abstract][Full Text] [Related]
33. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity.
Machado M; Valerio M; Álvarez-Uría A; Olmedo M; Veintimilla C; Padilla B; De la Villa S; Guinea J; Escribano P; Ruiz-Serrano MJ; Reigadas E; Alonso R; Guerrero JE; Hortal J; Bouza E; Muñoz P;
Mycoses; 2021 Feb; 64(2):132-143. PubMed ID: 33210776
[TBL] [Abstract][Full Text] [Related]
34. Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations.
Zurl C; Waller M; Schwameis F; Muhr T; Bauer N; Zollner-Schwetz I; Valentin T; Meinitzer A; Ullrich E; Wunsch S; Hoenigl M; Grinschgl Y; Prattes J; Oulhaj A; Krause R
J Fungi (Basel); 2020 Jun; 6(2):. PubMed ID: 32580296
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
[TBL] [Abstract][Full Text] [Related]
36. Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience.
Salas MQ; Mussetti A; Muñóz C; Albasanz-Puig A; Patiño B; Jimenez Prat L; Gudiol C; Parody R; Sureda A
Hematol Transfus Cell Ther; 2022; 44(3):440-443. PubMed ID: 33583766
[No Abstract] [Full Text] [Related]
37. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus dose modification in patients receiving concomitant isavuconazole after hematopoietic stem cell transplantation.
Trifilio S; Rubin H; Monacelli A; Mehta J
J Oncol Pharm Pract; 2021 Jun; 27(4):857-862. PubMed ID: 32659173
[TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
Azanza JR; Grau S; Vázquez L; Rebollo P; Peral C; López-Ibáñez de Aldecoa A; López-Gómez V
Mycoses; 2021 Jan; 64(1):66-77. PubMed ID: 32989796
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
Lachowiez CA; Loghavi S; Kadia TM; Daver N; Borthakur G; Pemmaraju N; Naqvi K; Alvarado Y; Yilmaz M; Short N; Ohanian M; Pierce SR; Patel KP; Qiao W; Ning J; Sasaki K; Takahashi K; Jabbour E; Andreeff M; Ravandi F; Kantarjian HM; Konopleva M; DiNardo CD
Blood Adv; 2020 Apr; 4(7):1311-1320. PubMed ID: 32251497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
